Jeffrey Vacirca
Hematology & Oncology · Port Jefferson Station, NYNPI 1366446726
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $90,000 of the $135,288 with a category attached, or 66.5%. Spectrum Pharmaceuticals Inc. accounts for 96.2% of it on its own, with 27 other manufacturers making up the rest. Reporting peaked in 2023 at $91,778 and has fallen 99.8% since, to $170 in 2024. Among hematology & oncology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 67 payments — averaging $2019.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Spectrum Pharmaceuticals Inc.$130K
- Ipsen Biopharmaceuticals, Inc$1K
- Genentech USA, Inc.$455
- Daiichi Sankyo Inc.$409
- Siemens Medical Solutions USA, Inc.$349
- ASD Specialty Healthcare, LLC$334
- plus $3K from 22 others
Across 30 payments — averaging $4605.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- La Jolla Pharmaceutical Company$130K
- Bayer$3K
- Spectrum Pharmaceuticals Inc.$3K
- Octapharma USA, Inc.$2K
- GSK$293
- Incyte Corporation$91
Across 1 payment — averaging $420,160 each. An ownership or investment interest held by the physician or an immediate family member.
- Caris MPI, Inc.$420K
What the payments were for
- Consulting fees$34,72526%
- Speaking & faculty fees$90,00067%
- Travel & lodging$5,3254%
- Food & beverage$4,8934%
- Gifts$3450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Spectrum Pharmaceuticals Inc. | 22 | $130,150 |
| Ipsen Biopharmaceuticals, Inc | 2 | $1,027 |
| Genentech USA, Inc. | 1 | $455 |
| Daiichi Sankyo Inc. | 2 | $409 |
| Siemens Medical Solutions USA, Inc. | 3 | $349 |
| ASD Specialty Healthcare, LLC | 4 | $334 |
| Sanofi | 2 | $190 |
| Karyopharm Therapeutics Inc. | 1 | $179 |
| G1 Therapeutics, Inc. | 1 | $175 |
| Puma Biotechnology, Inc. | 2 | $163 |
| Novartis | 1 | $157 |
| Varian Medical Systems, Inc. | 1 | $148 |
| Bayer | 1 | $146 |
| Amneal Pharmaceuticals LLC | 2 | $144 |
| Servier Pharmaceuticals LLC | 2 | $139 |
| Gilead(2 entities) | 6 | $135 |
| Amgen | 1 | $125 |
| Relievant Medsystems, Inc. | 1 | $125 |
| GSK | 1 | $117 |
| Genentech, Inc. | 1 | $114 |
| Sirtex Medical Inc | 1 | $100 |
| E.r. Squibb & Sons, L.L.C. | 1 | $94 |
| AstraZeneca | 2 | $87 |
| Epizyme, Inc. | 1 | $57 |
| Genmab U.S., Inc. | 1 | $56 |
| Johnson & Johnson | 2 | $46 |
| Taiho Oncology, Inc. | 1 | $36 |
| Verastem, Inc. | 1 | $33 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$135,288 in reported general payments places this provider in the 90th percentile of 967 hematology & oncology providers in New York.
Other hematology & oncology in Port Jefferson Station
- Alfredo TorresPort Jefferson Station$345K
- Michael SchusterNew York$1.6M
- Charles SawyersNew York$1.6M
- Manuel Hidalgo-MedinaNew York$1.4M
- Francis ArenaLake Success$1M
- Sanjeev JainEast Patchogue$971K
- Ross LevineNew York$968K
- Perry CookBrooklyn$803K
- Mihir RavalAlbany$767K
- Joshua SabariNew York$761K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.